Clinical Trials
65 trialsGEN1047 for Solid Tumors - First in Human (FIH) Trial
Genmab
PRO1107 in Patients With Advanced Solid Tumors
Genmab
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Ocellaris Pharma, Inc.
A Study of PF-06873600 in People With Cancer
Pfizer
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Shasqi, Inc.
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Alaunos Therapeutics
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Herlev Hospital
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Incyte Corporation
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Roswell Park Cancer Institute
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Numab Therapeutics AG
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Valerio Therapeutics
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Deciphera Pharmaceuticals, LLC
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Astellas Pharma Inc
REVOCAN
Gustave Roussy, Cancer Campus, Grand Paris
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Pfizer
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Opna Bio LLC
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
NantCell, Inc.
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Tango Therapeutics, Inc.
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
NantCell, Inc.
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
NextCure, Inc.
ORCHID-1
Medikine, Inc.
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Avenge Bio, Inc
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Sumitomo Pharma America, Inc.
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
THERAPIM PTY LTD
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
pharmaand GmbH
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
CytomX Therapeutics
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Akeso
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
City of Hope Medical Center
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Eisai Inc.
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
University of Wisconsin, Madison
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Abramson Cancer Center at Penn Medicine
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
SCRI Development Innovations, LLC
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Incyte Corporation
PAZOFOS
The Christie NHS Foundation Trust
PTX-200 and Carboplatin in Ovarian Cancer
Prescient Therapeutics, Ltd.
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
South Plains Oncology Consortium
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Lumos Pharma
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
AL3818
Advenchen Laboratories, LLC
SEASCAPE
Aduro Biotech, Inc.